The effect of liraglutide on endothelial function in patients with type 2 diabetes

Diabetes and Vascular Disease Research

Volumn 11, Issue 6, 2014, Pages 419-430

  Nandy, Debashis ^a   Johnson, Christopher ^a   Basu, Rita ^a   Joyner, Michael ^a   Brett, Jason ^b   Svendsen, Claus Bo ^c   Basu, Ananda ^a  

^a MAYO CLINIC   (United States)

^b NOVO NORDISK INC   (United States)

^c NOVO NORDISK A S   (Denmark)

Author keywords

endothelial function; Glucagon like peptide 1; liraglutide

Indexed keywords

ACETYLCHOLINE; BIOLOGICAL MARKER; C PEPTIDE; GLIMEPIRIDE; GLUCAGON; GLUCOSE; INSULIN; LIPID; LIRAGLUTIDE; N(G) METHYLARGININE; NITROPRUSSIDE SODIUM; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DOUBLE BLIND PROCEDURE; DYSPEPSIA; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPOGLYCEMIA; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY; VIRAL GASTROENTERITIS; VOMITING; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; MIDDLE AGED; PLETHYSMOGRAPHY; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MIDDLE AGED; NITROPRUSSIDE; PLETHYSMOGRAPHY;

EID: 84912035416     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164114547358     Document Type: Article

References (40)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002 ; 420: 868-874
2. Widlansky ME, Gokce N, Keaney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003 ; 42: 1149-1160
3. Hadi HAR, Al Suwaidi J. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007 ; 3: 853-876
4. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 ; 339: 229-234
5. Eskurza I, Seals DR, DeSouza CA, et al. Pharmacologic versus flow-mediated assessments of peripheral vascular endothelial vasodilatory function in humans. Am J Cardiol. 2001 ; 88: 1067-1069
6. Tagawa T, Mohri M, Tagawa H, et al. Role of nitric oxide in substance P-induced vasodilation differs between the coronary and forearm circulation in humans. J Cardiovasc Pharmacol. 1997 ; 29: 546-553
7. Hadi HAR, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005 ; 1: 183-198
8. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001 ; 104: 191-196
9. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001 ; 104: 2673-2678
10. Green DJ, Jones H, Thijssen D, et al. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter?. Hypertension. 2011 ; 57: 363-369
11. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006 ; 3: 153-165
12. Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab. 2007 ; 293: E1289 - E1295
13. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004 ; 287: E1209 - E1215
14. Vilsbøll T, Agersø H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003 ; 88: 220-224
15. Cho YM, Merchant CE, Kieffer TJ. Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacol Ther. 2012 ; 135: 247-278
16. Montanya E. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012 ; 13: 1451-1467
17. Elkinson S, Keating GM. Lixisenatide: first global approval. Drugs. 2013 ; 73: 383-391
18. Poole RM, Nowlan ML. Albiglutide: first global approval. Drugs. 2014 ; 74: 929-938
19. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010 ; 59: 1030-1037
20. Liu H, Dear AE, Knudsen LB, et al. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol. 2009 ; 201: 59-66
21. Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010 ; 53: 2256-2263
22. Gaspari T, Liu H, Welungoda I, et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res. 2011 ; 8: 117-124
23. Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med. 2012 ; 29: 1115-1118
24. Ding Y, Vaziri ND, Coulson R, et al. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab. 2000 ; 279: E11 - E17
25. Chai W, Dong Z, Wang N, et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. 2012 ; 61: 888-896
26. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004 ; 110: 955-961
27. Cabou C, Vachoux C, Campistron G, et al. Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ. Diabetes. 2011 ; 60: 2245-2256
28. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014 ; 114: 1788-1803
29. Ban K, Kim KH, Cho CK, et al. Glucagon-like peptide (GLP)-1(9-36) amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology. 2010 ; 151: 1520-1531
30. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013 ; 19: 567-575
31. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, et al. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol. 2012 ; 11: 64
32. Hopkins ND, Cuthbertson DJ, Kemp GJ, et al. Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients. Diabetes Obes Metab. 2013 ; 15: 770-773
33. Irace C, De Luca S, Shehaj E, et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res. 2013 ; 10: 72-77
34. Ayaori M, Iwakami N, Uto-Kondo H, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013 ; 2: e003277
35. Kubota Y, Miyamoto M, Takagi G, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012 ; 27: 1364-1370
36. Van Poppel PC, Netea MG, Smits P, et al. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011 ; 34: 2072-2077
37. Koska J, Schwartz EA, Mullin MP, et al. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care. 2010 ; 33: 1028-1030
38. Hermansen K, Baekdal TA, Düring M, et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial. Diabetes Obes Metab. 2013 ; 15: 1040-1048
39. Noda Y, Miyoshi T, Oe H, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol. 2013 ; 12: 8
40. Ardigo D, Franzini L, Valtuena S, et al. Relation of plasma insulin levels to forearm flow-mediated dilatation in healthy volunteers. Am J Cardiol. 2006 ; 97: 1250-1254